Neurology Solutions for more diagnostic confidence
By the time a typical Alzheimer’s disease (AD) patient comes to diagnosis, atrophy is normally well established. Even in patients with mild clinical symptoms, entorhinal volumes are already reduced by around 20–30 % and hippocampal volumes by about 15–25 %.1 In particular, the assessment of medial temporal atrophy with MRI has been shown to have a predictive value for AD. Consequently, medial temporal lobe atrophy is now included as one of the biomarkers of AD in proposed criteria for diagnosing (prodromal) AD at a pre-dementia stage.
3T MRI Scanners
Structural MRI in AD can assess atrophy and changes in tissue characteristics. Also, progressive cerebral atrophy can be visualized in patients, in particular, with T1-weighted volumetric sequences. MRI offers a range of different sequences that can probe different tissue characteristics, providing multiple clinical and research measures in a single session. MRI measures of atrophy reflect cumulative neuronal damage, which in turn is directly responsible for the clinical state.
The benefits of single modality MR and PET in the study of neurological diseases such as AD are well known. Combining these modalities brings the potential for a more complete imaging picture and better understanding of AD pathologies. In addition, the current research and development of new tracers offers great promise. Biograph mMR fully integrates state-of-the-art 3T MRI and cutting-edge molecular imaging. Simultaneous acquisition of the morphology, function, and metabolism of the brain are now possible. You can obtain a comprehensive diagnostic picture with just one scan, which shows MR and PET data in virtually seamless spatial alignment. In addition, the MR acquisition can be used to correct motion-related effects in PET, greatly improving image quality.
1Johnson KA et al. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med 2012;2:a006213